抗MDA5阳性皮肌炎合并间质性肺病的联合免疫抑制治疗前瞻性多中心研究
该多中心前瞻性研究纳入29例新发抗MDA5阳性皮肌炎合并间质性肺病的日本成人患者,采用大剂量糖皮质激素、他克莫司和静脉环磷酰胺联合方案,并与15例历史对照(阶梯治疗)比较。联合方案组6个月生存率显著高于对照组(89%对33%,P<0.0001),但巨细胞病毒再激活常见,需警惕机会性感染。
要点
- 联合方案组6个月生存率89%,显著高于阶梯治疗组的33%(P<0.0001)。
- 52周内抗MDA5滴度、血清铁蛋白、肺活量及胸部HRCT评分均有改善。
- 治疗期间巨细胞病毒再激活常见,需密切监测机会性感染。
核心结论
- 大剂量糖皮质激素、他克莫司和静脉环磷酰胺联合免疫抑制方案对延缓性抗MDA5阳性皮肌炎合并间质性肺病患者有效。
- 难治性病例可加用血浆置换以增强疗效。
- 治疗期间应密切监测机会性感染,尤其巨细胞病毒再激活。
研究设计与样本
- 多中心前瞻性研究,2014至2017年纳入29例新发抗MDA5阳性皮肌炎合并间质性肺病的日本成人患者。
- 治疗方案为大剂量糖皮质激素、他克莫司和静脉环磷酰胺,病情恶化时加用血浆置换。
- 主要终点为6个月生存率,与15例接受阶梯治疗的历史对照组比较。
主要发现
- 联合方案组6个月生存率显著高于阶梯治疗组(89%对33%,P<0.0001)。
- 52周内观察到抗MDA5滴度、血清铁蛋白水平、肺活量及胸部高分辨率CT评分改善。
- 联合方案组静脉环磷酰胺使用较对照组提前近20天且间隔更短,血浆置换使用倾向更高。
- 52周内巨细胞病毒再激活常见。
关键数值与推荐
- 主要终点6个月生存率:联合方案组89%,阶梯治疗组33%,P<0.0001。
临床怎么用
- 对 compat抗MDA5阳性皮肌炎合并间质性肺病患者可考虑早期采用大剂量糖皮质激素、他克莫司和静脉环磷酰胺联合方案。
- 难治性病例可加用血浆置换。
- 治疗全程需密切监测巨细胞病毒再激活等机会性感染。
局限性
- 对照组为历史对照,非随机同期对照。
- 样本量较小(联合组29例,对照组15例)。
- 研究对象为日本成人患者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (anti-MDA-5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we undertook this study to prospectively evaluate the efficacy and safety of a combined immunosuppressive regimen for anti-MDA-5-positive DM patients with ILD. METHODS: Adult Japanese patients with new-onset anti-MDA-5-positive DM with ILD (n = 29) were enrolled at multiple study centers from 2014 to 2017. They were treated with a regimen of high-dose glucocorticoids (GCs), tacrolimus, and intravenous cyclophosphamide (IV CYC). Plasmapheresis was used if a patient's condition worsened after the regimen started. The primary end point was 6-month survival, which was compared between this group of patients and a historical control group (n = 15) consisting of anti-MDA-5-positive DM patients with ILD who received step-up treatment (high-dose GC and stepwise addition of immunosuppressant). Secondary end points were 12-month survival rate, adverse events, and changes in laboratory data. RESULTS: The combined immunosuppressive regimen group showed significantly higher 6-month survival rates than the step-up treatment group (89% versus 33%; P < 0.0001). Over a period of 52 weeks, improvements in anti-MDA-5 titers, serum ferritin levels, vital capacity, and chest high-resolution computed tomography scores were observed. The combined immunosuppressive regimen group received IV CYC nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step-up treatment. Cytomegalovirus reactivation was frequently observed over 52 weeks. CONCLUSION: A combined immunosuppressive regimen is effective for anti-MDA-5-positive DM patients with ILD. Plasmapheresis can be used for additional effect in intractable disease. Patients should be carefully monitored for opportunistic infections during treatment.
引用
- Tsuji H, Nakashima R, Hosono Y, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020. PMID: 31524333. doi:10.1002/art.41105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。